Zucara Therapeutics to get US$ 2 million additional funding from JDRF to support ZT-01 phase 2 study

Zucara Therapeutics Inc., a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in diabetics, announced additional funding from JDRF, the world's leading T1D research and advocacy organisation. "JDRF has been a long-time partner of Zucara, supporting the development of ZT-01 from early discovery studies to this planned phase 2 study that is now underway," stated Richard Liggins PhD, chief scientific officer of Zucara Therapeutics. "We appreciate JDRF's ongoing support."

This grant demonstrates JDRF's commitment to advancing supplementary therapy to insulin, indicating a persistent unmet need for T1D patients. By restoring the body's ability to counter-regulate hypoglycemia, ZT-01 is intended to avoid potentially deadly low blood glucose levels. A-cells in persons who do not have diabetes secrete glucagon, which signals the body to release its own glucose stores, preventing hypoglycemia. The JDRF's purpose is to expedite life-changing breakthroughs in the cure, prevention, and treatment of type 1 diabetes and associated complications.

Since its foundation, JDRF has invested more than $2.5 billion in research financing. JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people.